Sandoz to Supreme Court: Circuit Erred in Ruling 180-Day Notification Required After Biosimilar Approval

Sandoz is arguing the Federal Circuit misinterpreted federal law when ruling that biosimilar makers must wait six months after an FDA approval to launch a product. 
Source: Drug Industry Daily